True North Commercial REIT Reports Q1-2025 Results
Completed 146,000 square feet of new and renewed leases during Q1-2025 with a weighted average lease term of 5.6 years and 1.6% leasing spread on renewed leases
TORONTO, May 12, 2025 /CNW/ - True North Commercial Real Estate Investment Trust (TSX: TNT.UN) (the "REIT") today announced its financial results for the three months ended March 31, 2025 ("Q1-2025").
"We are pleased to start the year with strong leasing momentum, completing 146,000 square feet of new or renewed leases, highlighting the REIT's commitment to maintain strong relationships with tenants which translated into reported occupancy within its core portfolio of 92%," stated Daniel Drimmer, the REIT's Chief Executive Officer. "The REIT also substantially completed the refinancing or renewal of its 2025 debt maturities at relatively favourable interest rates, which continued to strengthen the REIT's financial position."
Q1-2025 highlights
On March 18, 2025, the REIT announced the reinstatement of the monthly distribution ("Distribution Reinstatement") to Unitholders, which commenced with a record date of March 31, 2025, payable on April 15, 2025, amounting to $0.0575 per trust unit of the REIT ("Unit") per month.
The REIT's core portfolio occupancy (1) excluding assets held for sale at the end of Q1-2025 was approximately 92% which remained above the average occupancy for the markets in which the REIT operates. The REIT also had a weighted average lease term ("WALT") (1) of 4.2 years excluding investment properties held for sale.
The REIT contractually leased or renewed approximately 146,000 square feet with a WALT of 5.6 years with positive leasing spreads on renewals reported at 1.6% for the quarter.
Q1-2025 same property net operating income ("Same Property NOI") (1) increased by approximately 5.1% including certain amounts earned for termination income in both periods. Q1-2025 Same Property NOI normalized to exclude termination income, free rent in both periods and the REIT's Alberta portfolio would have increased by approximately 0.3%.
The REIT's Q1-2025 revenue and Net Operating Income ("NOI") (1) decreased relative to the three months ended March 31, 2024 ("Q1-2024") by 4% and 12%, respectively, primarily due to the disposition activity in 2024 (the "Primary Variance Driver") and a decrease in occupancy for the REIT's held for sale properties, partially offset by contractual rent increases and higher termination income received from a tenant in the Greater Toronto Area ("GTA") Ontario portfolio in Q1-2025 relative to the amounts received in Q1-2024.
The REIT's Q1-2025 funds from operations ("FFO") (1) and adjusted funds from operations ("AFFO") (1) decreased by $759 and $831, respectively when compared to the same period in 2024 primarily due to the Primary Variance Driver, reduction in occupancy for the REIT's held for sale properties and increase in interest costs, partially offset by normalized Same Property NOI growth outlined above. Q1-2025 FFO and AFFO basic and diluted per Unit (1) remained consistent at $0.56 and $0.57, respectively, compared to the same period in 2024, driven by a reduction in the number of Units as a result of the REIT's normal course issuer bid ("NCIB") program, offset by the reasons noted above for FFO and AFFO.
During Q1-2025, the REIT successfully completed $129,600 of refinancing or approximately 52% of the 2025 maturities and $4,500 of new financing at a weighted average interest rate of approximately 4.78% and weighted average term of approximately 3.6 years. Subsequent to March 31, 2025, the REIT successfully completed the refinancing of certain first mortgages totaling approximately $75,900 at an average interest rate of 4.68% representing approximately 30% of the 2025 debt maturities and has substantially finalized terms on an additional approximately $23,200 or 9% of 2025 debt maturities which are expected to be finalized by the second quarter of 2025. As a result, the REIT has substantially completed the renewal or refinancing of its 2025 debt maturities.
On April 23, 2025, the REIT renewed the NCIB program as approved by the TSX ("2025 NCIB"). Under the 2025 NCIB, the REIT has the ability to purchase for cancellation up to a maximum of 1,227,090 of its Units, representing 10% of the REIT's public float of 12,270,901 Units as of April 3, 2025 through the facilities of the TSX or through a Canadian alternative trading system and in accordance with applicable regulatory requirements at a price per Unit equal to the market price at the time of acquisition.
Key performance indicators
Q1-2025
Q1-2024
Number of properties (1)
40
44
Portfolio gross leasable area ("GLA") (1)
4,619,000 sf
4,792,600 sf
Occupancy (1)(2)
92 %
90 %
WALT (1)
4.2 years
4.4 years
Revenue from government and credit rated tenants (1)
74 %
77 %
Revenue
$ 31,086
$ 32,464
NOI
14,665
16,586
Net income and comprehensive income
563
5,138
Same Property NOI (3)
19,000
19,053
FFO
$ 8,082
$ 8,841
FFO per Unit - basic
0.56
0.56
FFO per Unit - diluted
0.56
0.56
AFFO
$ 8,229
$ 9,060
AFFO per Unit - basic
0.57
0.57
AFFO per Unit - diluted
0.57
0.57
AFFO payout ratio - diluted (4)
10 %
— %
Distributions declared
$ 828
$ —
(1) This is presented as at the end of the applicable reporting period, rather than for the quarter.
(2) Represents same property occupancy excluding assets classified as held for sale as at March 31, 2025. The REIT occupancy for all assets owned as at the end of each reporting period (including any held for sale assets) was 86% as at the end of Q1-2025 (Q1-2024 was 88%).
(3) Represents Same Property NOI including assets classified as held for sale during Q1-2025 and Q1-2024. Same Property NOI excluding assets classified as held for sale have been presented separately in this press release (see "Same Property NOI").
(4) This is a non-IFRS financial measure, refer to "Non-IFRS measures".
Operating results
Q1-2025 revenue and NOI decreased relative to the same period in 2024 by 4% and 12%, respectively, primarily due to the Primary Variance Driver and a decrease in occupancy for the REIT's held for sale properties, partially offset by contractual rent increases and higher termination income received from a tenant in the GTA Ontario portfolio in Q1-2025 relative to the amounts received in Q1-2024. Q1-2025 Same Property NOI increased by approximately 5.1% including certain amounts earned for termination income in both periods. Q1-2025 Same Property NOI normalized to exclude termination income, free rent in both periods and the REIT's Alberta portfolio would have increased by approximately 0.3%.
Q1-2025 FFO and AFFO decreased by $759 and $831, respectively when compared to the same period in 2024 primarily due to the Primary Variance Driver, reduction in occupancy for the REIT's held for sale properties and increase in interest costs, partially offset by normalized Same Property NOI growth outlined above.
Q1-2025 FFO and AFFO basic and diluted per Unit remained consistent at $0.56 and $0.57, respectively, compared to the same period in 2024, driven by reasons noted above for FFO and AFFO, being offset by a reduction in the number of Units as a result of the REIT's NCIB program.
On March 18, 2025, the REIT announced the Distribution Reinstatement to Unitholders, which commenced with a record date of March 31, 2025, payable on April 15, 2025, amounting to $0.0575 per Unit per month. Assuming distributions were paid for each month during Q1-2025, the AFFO payout ratio would have been approximately 30%.
Same Property NOI
Q1-2025 Same Property NOI excluding assets held for sale increased by approximately 5% compared to the same period in 2024. Same Property NOI included termination income of approximately $1,327 (Q1-2024 - $nil) and free rent credits of $186 (Q1-2024 - $72).
Q1-2025 Alberta Same Property NOI decreased by 10% primarily attributable to the downsizing of a tenant in the Calgary portfolio. Q1-2025 British Columbia Same Property NOI decreased by 26% primarily as a result of an expiring lease not renewed at the beginning of 2025. Occupancy and Same Property NOI on the remaining properties in British Columbia remained consistent.
Q1-2025 New Brunswick Same Property NOI increased by 3% compared to Q1-2024 due to a new lease with a government tenant that started in February 2025. Q1-2025 Nova Scotia Same Property NOI increased by 21% as a result of the increase in occupancy between the two periods driven by strong leasing activity.
Q1-2025 Ontario Same Property NOI increased by 10% relative to Q1-2024 primarily due to termination income received from a tenant in the GTA Ontario portfolio. Q1-2025 Ontario Same Property NOI excluding the impact of termination income and free rent would have been relatively consistent with the same period in the prior year.
Debt and liquidity
At the end of Q1-2025, the REIT had access to available funds ("Available Funds") (1) of approximately $56,612, and a weighted average term to maturity of 2.58 years in its mortgage portfolio with a weighted average fixed interest rate of 4.23%. Subsequent to March 31, 2025, the REIT successfully completed refinancing of certain first mortgages totaling approximately $75,900 at an average interest rate of 4.68%.
About the REIT
The REIT is an unincorporated, open-ended real estate investment trust established under the laws of the Province of Ontario. The REIT currently owns and operates a portfolio of 40 commercial properties consisting of approximately 4.6 million square feet in urban and select strategic secondary markets across Canada focusing on long term leases with government and credit rated tenants.
The REIT is focused on growing its portfolio principally through acquisitions across Canada and such other jurisdictions where opportunities exist. Additional information concerning the REIT is available at www.sedarplus.ca or the REIT's website at www.truenorthreit.com.
Non-IFRS measures
Certain terms used in this press release such as FFO, AFFO, FFO and AFFO payout ratios, NOI, Same Property NOI, indebtedness ("Indebtedness"), gross book value ("GBV"), Indebtedness to GBV ratio, net earnings before interest, tax, depreciation and amortization and fair value gain (loss) on financial instruments and investment properties ("Adjusted EBITDA"), interest coverage ratio, net asset value ("NAV") per Unit, Available Funds, occupancy and WALT are not measures defined by IFRS Accounting Standards ("IFRS") as prescribed by the International Accounting Standards Board, do not have standardized meanings prescribed by IFRS and should not be compared to or construed as alternatives to profit/loss, cash flow from operating activities or other measures of financial performance calculated in accordance with IFRS. FFO, AFFO, FFO and AFFO payout ratios, NOI, Same Property NOI, Indebtedness, GBV, Indebtedness to GBV ratio, Adjusted EBITDA, interest coverage ratio, adjusted cash provided by operating activities, NAV per Unit, Available Funds, occupancy and WALT as computed by the REIT may not be comparable to similar measures presented by other issuers. The REIT uses these measures to better assess the REIT's underlying performance and provides these additional measures so that investors may do the same. Details on non-IFRS measures are set out in the REIT's Management's Discussion and Analysis for Q1-2025 and the Annual Information Form are available on the REIT's profile at www.sedarplus.ca.
The following tables reconcile the non-IFRS financial measures to the comparable IFRS measures for Q1-2025 and Q1-2024. These non-IFRS financial measures do not have any standardized meanings prescribed by IFRS and may not be comparable to similar measures presented by other issuers.
Same Property NOI
Same Property NOI is measured as the NOI for the properties owned and operated by the REIT for the current and comparative period. The following table reconciles the REIT's Same Property NOI to NOI:
The following table reconciles the REIT's FFO and AFFO to net income and comprehensive income, for Q1-2025 and Q1-2024:
Q1-2025
Q1-2024
Net income and comprehensive income
$ 563
$ 5,138
Add (deduct):
Fair value adjustment of Unit-based compensation
(66)
(46)
Fair value adjustment of investment properties and investment properties held for sale
3,832
1,898
Fair value adjustment of Class B LP Units
(306)
(337)
Distributions on Class B LP Units
24
—
Unrealized loss (gain) on change in fair value of derivative instruments
525
(253)
Amortization of leasing costs and tenant inducements
3,510
2,441
FFO
$ 8,082
$ 8,841
Add (deduct):
Unit-based compensation expense
122
81
Amortization of financing costs
330
363
Amortization of mortgage discounts
(3)
(8)
Instalment note receipts
11
12
Straight-line rent
826
966
Capital reserve
(1,139)
(1,195)
AFFO
$ 8,229
$ 9,060
FFO per Unit:
Basic
$ 0.56
$ 0.56
Diluted
0.56
0.56
AFFO per Unit:
Basic
$ 0.57
$ 0.57
Diluted
0.57
0.57
AFFO payout ratio:
Basic
10 %
— %
Diluted
10 %
— %
Distributions declared
$ 828
$ —
Weighted average Units outstanding (000s):
Basic
14,458
15,861
Add:
Unit options and incentive Units
78
10
Diluted
14,536
15,871
Indebtedness to GBV ratio
The table below calculates the REIT's Indebtedness to GBV ratio as at March 31, 2025 and December 31, 2024. The Indebtedness to GBV ratio is calculated by dividing the Indebtedness by GBV:
Adjusted EBITDA
The table below reconciles the REIT's Adjusted EBITDA to net loss and comprehensive loss for the twelve months period ended March 31, 2025 and 2024:
Interest coverage ratio
The table below calculates the REIT's interest coverage ratio for the twelve months period ended March 31, 2025 and 2024. The interest coverage ratio is calculated by dividing Adjusted EBITDA by interest expense.
Available Funds
The table below calculates the REIT's Available Funds as at March 31, 2025 and December 31, 2024:
Forward-looking statements
Certain statements contained in this press release constitute forward-looking information within the meaning of Canadian securities laws. Forward-looking statements are provided for the purposes of assisting the reader in understanding the REIT's financial performance, financial position and cash flows as at and for the periods ended on certain dates and to present information about management's current expectations and plans relating to the future. Readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information may relate to future results, performance, debt financing, achievements, events, prospects or opportunities for the REIT or the real estate industry and may include statements regarding the financial position, business strategy, budgets, projected costs, capital expenditures, financial results, taxes, distributions, plans, the benefits and renewal of the NCIB, or through other capital programs, the impact of the consolidation (the "Unit Consolidation") and objectives of or involving the REIT. In some cases, forward-looking information can be identified by such terms as "may", "might", "will", "could", "should", "would", "expect", "plan", "anticipate", "believe", "intend", "seek", "aim", "estimate", "target", "goal", "project", "predict", "forecast", "potential", "continue", "likely", or the negative thereof or other similar expressions suggesting future outcomes or events.
Forward-looking statements involve known and unknown risks and uncertainties, which may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, assumptions may not be correct and objectives, strategic goals and priorities may not be achieved. A variety of factors, many of which are beyond the REIT's control, affect the operations, performance and results of the REIT and its business, and could cause actual results to differ materially from current expectations of estimated or anticipated events or results. These factors include, but are not limited to: risks and uncertainties related to the Units and trading value of the Units; risks related to the REIT and its business; fluctuating interest rates and general economic conditions, including potential higher levels of inflation; the impact of any tariffs and retaliatory tariffs on the economy, credit, market, operational and liquidity risks generally; occupancy levels and defaults, including the failure to fulfill contractual obligations by tenants; lease renewals and rental increases; the ability to re-lease and secure new tenants for vacant space; the timing and ability of the REIT to acquire or sell certain properties; work-from-home flexibility initiatives on the business, operations and financial condition of the REIT and its tenants, as well as on consumer behavior and the economy in general; the ability to enforce leases, perform capital expenditure work, increase rents, raise capital through the issuance of Units or other securities of the REIT; the benefits of the NCIB, or through other capital programs; the impact of the Unit Consolidation; the ability of the REIT to continue to pay distributions in future periods; and obtain mortgage financing on the REIT's properties and for potential acquisitions or to refinance debt at maturity on similar terms. The foregoing is not an exhaustive list of factors that may affect the REIT's forward-looking statements. Other risks and uncertainties not presently known to the REIT could also cause actual results or events to differ materially from those expressed in its forward-looking statements. The reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements as there can be no assurance actual results will be consistent with such forward-looking statements.
Information contained in forward-looking statements is based upon certain material assumptions applied in drawing a conclusion or making a forecast or projection, including management's perception of historical trends, current conditions and expected future developments, as well as other considerations believed to be appropriate in the circumstances. There can be no assurance regarding: (a) work-from-home initiatives on the REIT's business, operations and performance, including the performance of its Units; (b) the REIT's ability to mitigate any impacts related to fluctuating interest rates, potential higher levels of inflation; the impact of any current or future tariffs and the shift to hybrid working; (c) the factors, risks and uncertainties expressed above in regards to the hybrid work environment on the commercial real estate industry and property occupancy levels; (d) credit, market, operational, and liquidity risks generally; (e) the availability of investment opportunities for growth in Canada and the timing and ability of the REIT to acquire or sell certain properties; (f) repurchasing Units under the NCIB; (g) Starlight Group Property Holdings Inc., or any of its affiliates, continuing as asset manager of the REIT in accordance with its current asset management agreement; (h) the benefits of the NCIB, or through other capital programs; (i) the impact of the Unit Consolidation; (j) the availability of debt financing for potential acquisitions or refinancing loans at maturity on similar terms; (k) the ability of the REIT to continue to pay distributions in future periods; and (l) other risks inherent to the REIT's business and/or factors beyond its control which could have a material adverse effect on the REIT.
The forward-looking statements made relate only to events or information as of the date on which the statements are made. Except as specifically required by applicable Canadian law, the REIT undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
43 minutes ago
- Cision Canada
Clarivate Identifies Radioligand Therapy Innovators as Companies to Watch in the Future of Precision Oncology
New Report Highlights Emerging Leaders Advancing Next-generation Radiopharmaceuticals, Reshaping Cancer Care Through Targeted Innovation and Strategic Growth LONDON, June 16, 2025 /CNW/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the release of a new Companies to Watch report, Radioligand Innovators Ushering in a New Era of Precision Oncology. The report spotlights pioneering companies that are redefining the drug discovery and development landscape through advancements in radioligand therapies (RLTs)—a rapidly evolving class of therapeutics that combines nuclear medicine with precision-targeted biotechnology to treat cancer with heightened specificity. Drawing on proprietary data, expert analysis and insights into therapeutic benefit, financing activity and R&D momentum, the report highlights why these organizations are considered high-impact innovators. This latest edition follows previous Companies to Watch reports focused on RNA-based technologies, artificial intelligence/ machine learning (AI/ML), next-generation gene-editing and antibody-drug conjugates (ADCs). Radioligand therapies represent one of the most promising frontiers in oncology, offering highly specific delivery of radioactive isotopes to tumor cells while minimizing damage to healthy tissue. These agents are rapidly gaining momentum as both scientific breakthroughs and strategic investments accelerate across the global pharmaceutical landscape. Michael Ward, Global Head of Thought Leadership, Life Sciences & Healthcare, Clarivate, said: "Radioligand therapies are emerging as a cornerstone of precision oncology, combining decades of research in nuclear medicine with the latest innovations in biotechnology. This report identifies the innovators that are pushing the boundaries of what's possible in cancer care — and highlights the market, scientific and strategic signals that make them companies to watch." David Bejker, Chief Executive Officer, Affibody, said: "Radioligand therapies (RLTs) are transforming the promise of precision medicine into reality, enabling treatments that are finely tuned to the unique characteristics of each patient and their tumor, rather than relying on one-size-fits-all solutions. By uniting the precision of targeted drug delivery with the power of radiotherapy, RLTs use tumor-seeking molecules linked to therapeutic radioisotopes to deliver radiation directly to cancer cells, minimizing damage to healthy tissue and opening a new frontier in personalized cancer care." The report offers a detailed view of the evolving RLT landscape, highlighting the science, clinical promise and market momentum behind this precision approach. It profiles emerging innovators; explores key trends in M&A, funding and partnerships; and examines how differentiated R&D strategies and IP positioning set companies apart. The report also addresses challenges in manufacturing and regulation while assessing advances in alpha-emitting isotopes, combination therapies and the infrastructure needed to deliver next-generation radiotherapies at scale. The Radioligand Companies to Watch are: Affibody, founded by researchers at the KTH Royal Institute of Technology and Karolinska Institutet, has a mission of addressing medical needs with pioneering treatments that can improve the lives of patients with serious diseases. As a clinical stage biopharmaceutical company, it has pre-clinical and clinical development programs in oncology and immunology, with a broad product pipeline focused on developing innovative next-generation biopharmaceutical drugs based on its proprietary technology platform, Affibody® molecules. Alpha-9 Oncology is developing and advancing a pipeline of differentiated and highly targeted radiopharmaceuticals as potentially life-improving treatments for various malignancies. The company's bespoke, iterative process leverages the team's deep expertise in modifying peptides, small molecules and small biologics to inform target selection, molecule design, formulation and clinical evaluation. Ariceum Therapeutics was launched after the acquisition of the rights for its lead product, satoreotide (SSO110), from Ipsen, which has remained a shareholder in the company. Satoreotide is a proprietary peptide derivative that binds to somatostatin receptor 2 (SSTR2), which is overexpressed in neuroendocrine tumors and some aggressive cancers. The company is developing radiopharmaceutical theranostic pairs focusing on aggressive tumors such as small-cell lung cancer (SCLC) and Merkel cell carcinoma (MCC). Convergent Therapeutics is developing radioantibodies, by conjugating alpha radionuclides to antibodies that target cancer cells. Its lead candidate, CONV01-α (Ac-225 rosopatamab tetraxetan), is in phase 2 trials for prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Perspective Therapeutics, a clinical-stage, radiopharmaceutical company, has adopted a theranostic approach using its proprietary chelator technology platform that enables radiolabeling of targeting moieties against cancers with therapeutic isotopes of lead (Pb-212) or diagnostic isotopes such as Ga-68 for high-resolution imaging of uptake or Pb-203 for retention of uptake. The company has also entered into exclusive licensing and patent agreements with academic institutions to broaden its alpha-emitting radiopharmaceutical platform capabilities. PRECIRIX®, founded as a spin-off from Vrije Universiteit Brussel (VUB), is designing and developing radiopharmaceutical theranostics using camelid single-domain antibodies (sdAb) labeled with radiometals against multiple targets. The company's lead program, which targets fibroblast activation protein (FAP), could be a best-in-class alpha-emitting targeted radiotherapy against FAP and has been designed to address FAP-positive tumors. Notable developments shaping the RLT field include high-profile acquisitions — such as Bristol Myers Squibb's $4.1 billion purchase of RayzeBio and AstraZeneca's $2.4 billion acquisition of Fusion Pharmaceuticals — as well as blockbuster therapies like Novartis' PLUVICTO® and LUTATHERA®, which have paved the way for broader adoption. As the global radiopharmaceutical market is projected to surpass $13 billion within the next decade, the companies featured in this report are well-positioned to lead the next wave of therapeutic innovation. To download the full report or learn more, visit here. Methodology for the Companies to Watch Report Clarivate analysts employed a rigorous, multidimensional framework to identify the emerging innovators featured in this Companies to Watch report. Each company was assessed for its ability to address critical scientific, clinical and business challenges within the radioligand therapy space. Key considerations included demonstrated proof of concept, achievement of developmental milestones and positioning within the clinical trial landscape. The evaluation also factored in the strength of collaborations with leading academic and research institutions, the potential to address significant unmet medical needs and the overall burden of disease targeted by each therapy. Financial health was a further determinant, with analysts examining capital raised, investor partnerships, projected runway and prospects for future growth through fundraising or strategic alliances. Finally, each company's intellectual property estate was analyzed to understand the strength and breadth of its innovation pipeline. The assessment was underpinned by insights from Clarivate's trusted proprietary data sources, including Cortellis Competitive Intelligence™, Cortellis Deals Intelligence™, Cortellis Regulatory Intelligence™, Cortellis Clinical Trials Intelligence™, BioWorld™ and OFF-X™ Translational Safety Intelligence, ensuring a holistic view of the companies poised to shape the future of precision oncology.
Cision Canada
43 minutes ago
- Cision Canada
GETCHELL GOLD CORP. ANNOUNCES CLOSING OF UPSIZED $4 MILLION FINANCING AND CONVERSION OF FIRST TRANCHE OF DEBENTURES
VANCOUVER, BC, June 16, 2025 /CNW/ - Getchell Gold Corp. (CSE: GTCH) (OTCQB: GGLDF) (FWB: GGA1) ("Getchell" or the "Company") is pleased to announce that it has closed its previously announced private placement financing of units (" Units") for gross proceeds of $4,000,000 (the " Offering") and has converted the first tranche of outstanding debentures (the " Debentures") in the principal amount of amount of $3,612,888 and accrued interest in the amount of $543,841.20 into Units, on the same terms as the Offering (the " Debenture Conversion Option"). Key Highlights Completes $4M Unit financing, upsized due to investor demand Includes $1.2M order from lead investor, Myrmikan Gold Fund LLC. Offering to fund 2025 drill program at Fondaway Canyon gold project in Nevada $3,612,888 conversion of principal Debenture in first tranche close 82.8% Debenture conversion rate Major debt reduction significantly improves confidence and strengthens the foundation for future value accretion Outstanding Debenture holders have until Friday, June 20, 2025, to convert the Debenture "The incredible response and support we have received, from our investors and the investment community at large, is a testament to the unrealized value and great opportunity that the Fondaway Canyon gold project represents. It is a belief we strongly echo and one we intend to aggressively pursue. With the close of the Offering behind us, we can return our focus to getting back to the field and discovering more gold in the ground." stated Bob Bass, Chairman. Offering The Company has closed its previously announced private placement financing of Units at a price of $0.20 per Unit for gross proceeds of $4,000,000 (the " Offering"). The Offering was upsized from $3 million to $4 million and included a $1.2 million order from lead investor, Myrmikan Gold Fund LLC. Each Unit is comprised of one common share of the Company and one-half of one common share purchase warrant. Each whole warrant is exercisable into one common share of the Company at an exercise price of $0.30 per share until June 13, 2028. In connection with the Offering, the Company paid a total of $52,140 in cash and issued an aggregate of 260,700 finder's warrants (the " Finder's Warrants") to arm's length finders. This compensation represents 6.0% of the gross proceeds raised and 6.0% of the Units sold where subscribers were introduced to the Company in connection with the Offering. Each Finder's Warrant entitles the holder to acquire one common share of the Company at a price of $0.30 per share until June 13, 2028. The Company intends to use the proceeds of the Offering to spearhead the 2025 exploration program at the Fondaway Canyon gold project, as set out in greater detail in the Company's news release dated May 26, 2025. Debenture Conversion In addition, the Company announces that it has converted the first tranche of debentures (the " Debentures") in the principal amount of amount of $3,612,888, representing an 82.8% conversion rate, and accrued interest in the amount of $543,841.20 into Units, on the same terms as the Offering (the " Debenture Conversion Option"). The conversion of the vast majority of the Debentures generates the immediate positive impact of reducing risk, improving confidence, and strengthening the balance sheet, thereby providing a stronger foundation for value accretion in the future. Participating Debentureholders agreed to voluntarily convert Debentures and accrued in exchange for an aggregate of 20,783,646 Units. In connection with the first tranche, the Company has also accelerated the vesting date of 6,059,500 Debenture Warrants such that the Debenture Warrants vested on June 13, 2025. On December 29, 2023, January 26, 2024, and May 2, 2024, the Company issued Debentures in the aggregate principal amount of $4,363,318 (the " Debenture Financing"). The Debentures bear interest at 11% per annum and mature three years from the date of issuance. Debentureholders also received an aggregate of 43,633,180 warrants (the " Debenture Warrants"). Each Debenture Warrant is exercisable at a price of $0.10 per share for a period of three years from the date of issuance. 50% of the Debenture Warrants vested on the date of issuance and the remaining 50% vest 14 months following the closing of each tranche of the Debenture Financing. The Company is continuing its outreach to Debentureholders with a deadline for the receipt of executed Debenture Conversion agreements prior to Friday, June 20, 5:00pm PT, to be included in the closing of a second tranche of the Debenture Conversion Option. Debentures in the aggregate principal amount of $750,430 remain outstanding, and the rights of Debentureholders who have not elected to convert their Debentures remain unchanged. All securities issued under the Offering and the first tranche of the Debenture Conversion Option are subject to a four month hold period, expiring on October 14, 2025, in accordance with applicable Canadian securities laws. The securities offered have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or applicable exemption from the registration requirements. MI 61-101 Disclosure Pursuant to the Debenture Conversion Option, directors Bob Bass and Chris Bass and Corporate Secretary William Wagener converted an aggregate of $1,403,524 in Debentures and accrued interest into 7,017,620 Units. These conversions are considered "related party transactions" pursuant to Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions (" MI 61-101"). The Company relied on the exemptions from the formal valuation requirements contained in section 5.5(b) of MI 61-101 and the minority shareholder approval requirements contained in section 5.7(1)(a) of MI 61-101, as the Company is not listed on specified markets and the fair market value of the Units issued on conversion of the insider's Debentures do not exceed 25% of the Company's market capitalization, as determined in accordance with MI 61-101. The Company did not submit a material change report at least 21 days prior to the closing of the transaction due to the Company's desire to close expeditiously. Early Warning Disclosure On June 13, 2025, Mr. Bob Bass of Toronto, Ontario acquired 6,318,500 Units from the Company, at $0.20 per Unit, pursuant to the Debenture Conversion Option. Each Unit is comprised of one common share of the Company and one half of one Warrant, with each Warrant exercisable into an additional common share of the Issuer at a price of $0.30 per share until June 13, 2028. Mr. Bass converted a total of $1,263,700 in Debentures and accrued interest to the Units. Immediately prior to the conversion of his Debentures, Mr. Bass owned, or had control or direction over, directly or indirectly, 13,276,936 common shares, 9,950,000 warrants, 1,250,000 options, and 1,000,000 restricted share units (" RSUs") of the Company, representing approximately 9.25% of the Company's then issued and outstanding shares, on an undiluted basis, or 16.36% on a partially diluted basis. Following the conversion, Mr. Bass owns or has control or direction over, directly or indirectly, 19,595,436 common shares, 13,109,250 warrants, 1,250,000 options, and 1,000,000 RSUs of the Company, representing approximately 10.63% of the Company's issued and outstanding shares, on an undiluted basis, or 17.51% on a partially diluted basis. Since Mr. Bass' last early warning report on April 30, 2024, he has acquired an aggregate of 3,199,792 common shares of the Company, 1,500,000 of which were through the exercise of warrants at $0.10 per share, and the remaining 1,699,792 being through shares issued at various prices as consideration for director services, and as purchased by Mr. Bass at various market prices through the facilities of the Canadian Securities Exchange. Mr. Bass also received 1,250,000 options and 1,000,000 RSUs since his last early warning report as part of his compensation from the Company for director services. In aggregate, Mr. Bass' holdings, from the date of his last early warning report, have increased 2.85%, on an undiluted basis, or 2.23%, on a partially diluted basis. Mr. Bass acquired the Units through the Debenture Conversion for investment purposes. Mr. Bass may, depending on market and other conditions, increase or decrease his ownership in the Company's securities, whether in the open market, by privately negotiated agreements or otherwise, subject to a number of factors, including general market conditions and other available investment and business opportunities. The disclosure respecting Mr. Bass' security holdings of the Company contained in this press release is made pursuant to National Instrument 62-103 The Early Warning System and Related Take Over Bids and Insider Reporting Issues and a report respecting the above disposition will be filed with the applicable securities commissions using the Canadian System for Electronic Document Analysis and Retrieval (SEDAR+) and will be available for viewing at About Getchell Gold Corp. The Company is a Nevada focused gold and copper exploration company trading on the CSE: GTCH, OTCQB: GGLDF, and FWB: GGA1. Getchell Gold is primarily directing its efforts on its most advanced stage asset, Fondaway Canyon, a past gold producer with a large mineral resource estimate and recently published Preliminary Economic Assessment. The Canadian Securities Exchange has not reviewed this press release and does not accept responsibility for the adequacy or accuracy of this news release. Certain information contained herein constitutes "forward-looking information" under Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the use of proceeds from the Offering, the Company closing further tranches of the Debenture Conversion Option, future exploration success, and valuation growth. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "will" or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made, and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Although management of Getchell have attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws. SOURCE Getchell Gold Corp.
Cision Canada
44 minutes ago
- Cision Canada
Pierre Fabre Laboratories Strengthen R&D Portfolio and Announce the Acquisition of the Worldwide Rights for PFL-721 and PFL-241
PFL-721 and PFL-241 are mutant-specific EGFR inhibitors with best-in-class potential, being developed as treatment options for emergent and unmet medical needs in non-small cell lung cancer ("NSCLC") CASTRES, France, June 16, 2025 /CNW/ -- Pierre Fabre Laboratories are pleased to announce the acquisition from Antares Therapeutics, Inc. ("Antares"), a spin-out of Scorpion Therapeutics, Inc., of the worldwide rights for PFL-721 and PFL-241 (formerly known as STX-721 and STX-241, respectively). Under the terms of the agreement, Pierre Fabre Laboratories will expand its previous agreement with Scorpion Therapeutics to hold the global rights for both assets and will be leading the clinical development of both programs. View PDF PFL-721 is a mutant-specific EGFR exon 20 and HER2 exon 20 inhibitor, soon to transition to dose optimization within a first-in-human trial in NSCLC. PFL-241 is a mutant-specific, brain penetrant, 4th generation EGFR inhibitor, currently in dose escalation in a first-in-human trial, to address C797S resistance mutations in NSCLC patients. NSCLC is the most common sub-type of lung cancer and various EGFR mutations are the most frequent drivers of NSCLC, occurring in approximately 14-38 percent of tumors, depending on geography. [1], [2], [3] "With this agreement with Antares, Pierre Fabre Laboratories now own the global rights for all the assets within our R&D portfolio: exarafenib, PFL-002 (formerly VERT-002), PFL-721 and PFL-241. The R&D team is fully engaged and committed to progress the clinical development of these programs, aiming at providing novel and differentiated precision medicines to patient populations with significant unmet needs." said Francesco Hofmann, Head of Research and Development for Medical Care at Pierre Fabre Laboratories. About Pierre Fabre Laboratories Pierre Fabre Laboratories is the world's second-largest dermo-cosmetics company and one of Europe's leading pharmaceutical laboratories. Its Dermo-cosmetics & Personal Care portfolio includes international brands such as Eau Thermale Avène, Ducray, Klorane, A-Derma, René Furterer, Même Cosmetics, Darrow and Elgydium. Its Medical Care activity covers 5 main therapeutic fields: oncology, dermatology, rare diseases, primary care and family health care. [1] The Prevalence of EGFR Mutation in Patients with Non-Small Cell Lung Cancer, Oncotarget, October 2016 [2] EGFR Mutation Incidence in Non-Small Cell Lung Cancer, J Cancer Res., August 2015 [3] Molecular Epidemiology of EGFR Mutations in Asian Patients, PLoS ONE, November 2015
